Skip to main content
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2022 Jun 7;23(1):64. doi: 10.1186/s10194-022-01434-8

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti 1,2,, Gabriella Egeo 1, Cinzia Aurilia 1, Florindo d’Onofrio 3, Maria Albanese 4,5, Ilaria Cetta 6, Paola Di Fiore 7, Maurizio Zucco 8, Massimo Filippi 9, Francesco Bono 10, Claudia Altamura 11, Stefania Proietti 12, Stefano Bonassi 12,13, Fabrizio Vernieri 14; for the FRIEND-Study Group
PMCID: PMC9172000  PMID: 35672670

Correction: J Headache Pain 23, 46 (2022)

https://doi.org/10.1186/s10194-022-01396-x

Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5.

The original article has been corrected.

Reference

  • 1.Barbanti, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) J Headache Pain. 2022;23:46. doi: 10.1186/s10194-022-01396-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES